These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 26103822)

  • 1. [Response regarding "HIV encephalopathy due to drug resistance despite 2-year suppression of HIV viremia by cART"].
    Sekiya H; Kawamoto M; Togo M; Yoshimura H; Imai Y; Kohara N
    Rinsho Shinkeigaku; 2015; 55(6):437. PubMed ID: 26103822
    [No Abstract]   [Full Text] [Related]  

  • 2. [Encephalopathy in HIV patients on antiretroviral therapy].
    Kishida S
    Rinsho Shinkeigaku; 2015; 55(6):435-6. PubMed ID: 26103821
    [No Abstract]   [Full Text] [Related]  

  • 3. [HIV encephalopathy due to drug resistance despite 2-year suppression of HIV viremia by cART].
    Sekiya H; Kawamoto M; Togo M; Yoshimura H; Imai Y; Kohara N
    Rinsho Shinkeigaku; 2014; 54(9):721-5. PubMed ID: 25283826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of HIV-1 viremia or sexually transmitted infection on semen-derived anti-HIV-1 antibodies and the immunosuppressive capacity of seminal plasma.
    Selva KJ; Bavinton BR; Grulich AE; Pazgier M; Kelleher AD; Kent SJ; Parsons MS
    Eur J Immunol; 2019 Dec; 49(12):2255-2258. PubMed ID: 31621073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV encephalitis despite suppressed viraemia: a case of compartmentalized viral escape.
    Bingham R; Ahmed N; Rangi P; Johnson M; Tyrer M; Green J
    Int J STD AIDS; 2011 Oct; 22(10):608-9. PubMed ID: 21998185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of residual plasma viremia and intima-media thickness in antiretroviral-treated patients with controlled human immunodeficiency virus infection.
    Boyd A; Meynard JL; Morand-Joubert L; Michon A; Boccara F; Bastard JP; Samri A; Haddour N; Mallat Z; Capeau J; Desvarieux M; Girard PM;
    PLoS One; 2014; 9(11):e113876. PubMed ID: 25415323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Slow or fast viral load decay as a predictor of residual viremia level in HIV-infected patients undergoing successful first-line cART.
    Amendola A; Bibbolino G; Navarra A; Pisciotta M; Marsella P; Pinnetti C; Abbate I; Rozera G; Mondi A; Antinori A; Capobianchi MR; Girardi E; Ammassari A
    New Microbiol; 2017 Oct; 40(4):234-241. PubMed ID: 29184963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of Control of HIV Viremia With OTC Weight-Loss Drugs: A Call for Caution?
    Cattaneo D; Giacomelli A; Gervasoni C
    Obesity (Silver Spring); 2018 Aug; 26(8):1251-1252. PubMed ID: 30070075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Monitoring anti-retroviral treatment].
    Miró JM; Pumarola T; Soriano V; Bouza E
    Enferm Infecc Microbiol Clin; 1996 Oct; 14 Suppl 1():44-50. PubMed ID: 9053027
    [No Abstract]   [Full Text] [Related]  

  • 10. Relapse of Kaposi's Sarcoma and HHV-8 viremia in an HIV-infected patient switching from protease inhibitor to integrase inhibitor-based antiretroviral therapy.
    Simonetti FR; Ricaboni D; Cattaneo D; Micheli V; Rusconi S; Gervasoni C
    J Clin Virol; 2016 Jan; 74():75-7. PubMed ID: 26682615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is the glass three-quarters full or one-quarter empty?
    McArthur JC; Letendre SL
    J Infect Dis; 2006 Dec; 194(12):1628-31. PubMed ID: 17109332
    [No Abstract]   [Full Text] [Related]  

  • 12. Reconsidering early HIV treatment and supervised treatment interruptions.
    Koup RA
    PLoS Med; 2004 Nov; 1(2):e41. PubMed ID: 15578109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pretreatment antiretroviral exposure from recreational use.
    Grelotti DJ; Closson EF; Mimiaga MJ
    Lancet Infect Dis; 2013 Jan; 13(1):10-2. PubMed ID: 23257221
    [No Abstract]   [Full Text] [Related]  

  • 14. Low-level viremia in HIV-1 infection: consequences and implications for switching to a new regimen.
    Cohen C
    HIV Clin Trials; 2009; 10(2):116-24. PubMed ID: 19487182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multidrug resistance: a clinical approach.
    Yazdanpanah Y
    Curr Opin HIV AIDS; 2009 Nov; 4(6):499-506. PubMed ID: 20048717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical and virological correlation between the cerebrospinal fluid and blood of HIV-infected children].
    Sáez-Llorens X; Castrejón de Wong MC; Castaño E; de Suman O; Báez de Ulloa C; Redondo W; Espino M
    Rev Med Panama; 2001; 26():13-8. PubMed ID: 16161718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunological and virological impact of highly active antiretroviral therapy initiated during acute HIV-1 infection.
    Streeck H; Jessen H; Alter G; Teigen N; Waring MT; Jessen A; Stahmer I; van Lunzen J; Lichterfeld M; Gao X; Allen TM; Carrington M; Walker BD; Rockstroh JK; Altfeld M
    J Infect Dis; 2006 Sep; 194(6):734-9. PubMed ID: 16941338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuropharmacology.
    Winston A; Manji H
    Handb Clin Neurol; 2018; 152():55-64. PubMed ID: 29604984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [When to start antiretroviral therapy].
    Elzi L; Battegay M
    Ther Umsch; 2014 Jan; 71(1):23-9. PubMed ID: 24394206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [GESIDA/National AIDS Plan: Consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (Updated January 2015)].
    Panel de expertos de GeSIDA y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2015 Oct; 33(8):543.e1-43. PubMed ID: 25959461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.